Vericiguat for Heart Failure: Benefits & Research
- For individuals living with chronic heart failure and reduced ejection fraction (HFrEF), a new picture is emerging regarding the benefits of vericiguat (Verquvo, co-developed by Merck and Bayer).Recent...
- Heart failure with reduced ejection fraction (HFrEF) occurs when the heart muscle doesn't contract effectively, leading to a reduced ability to pump blood throughout the body.
- The initial results from the VICTOR trial showed that vericiguat, a soluble guanylate cyclase (sGC) stimulator, lowered the risk of all-cause and cardiovascular death when compared to a...
Vericiguat Shows Promise in Heart Failure Treatment, New Analyses Reveal
Table of Contents
Updated September 1, 2025, at 10:13 AM
For individuals living with chronic heart failure and reduced ejection fraction (HFrEF), a new picture is emerging regarding the benefits of vericiguat (Verquvo, co-developed by Merck and Bayer).Recent research presented at the European Society of cardiology Congress indicates the oral medication demonstrates a significant reduction in both all-cause mortality and cardiovascular (CV) death.
Initial Findings from the VICTOR Trial
The initial results from the VICTOR trial showed that vericiguat, a soluble guanylate cyclase (sGC) stimulator, lowered the risk of all-cause and cardiovascular death when compared to a placebo. However, the trial, on its own, did not demonstrate a statistically significant reduction in hospitalizations specifically due to heart failure.
Combined Data Offer Broader Benefits
A crucial development came with a meta-analysis combining the data from the VICTOR trial with findings from the earlier VICTORIA trial. This combined analysis revealed a more complete benefit: vericiguat was associated with a reduced risk of both cardiovascular death and heart failure hospitalization compared to placebo. This suggests that the medication’s positive effects are amplified when considering a broader patient population and a more extensive dataset.
How Vericiguat Works
Vericiguat works by stimulating sGC, an enzyme that plays a key role in relaxing blood vessels. By enhancing this process, the medication helps to improve blood flow and reduce the strain on the heart. This mechanism of action offers a novel approach to treating HFrEF, particularly in patients who remain symptomatic despite receiving standard therapies.
These findings underscore the potential of vericiguat to improve outcomes for patients with heart failure and reduced ejection fraction, especially when considered in the context of broader clinical data.
What This Means for Patients
These findings offer a hopeful advancement in the treatment of HFrEF. While further research is always ongoing, the combined data from VICTOR and VICTORIA suggest that vericiguat could become a valuable addition to the toolkit for managing this challenging condition. Patients should discuss with their healthcare providers whether vericiguat is an appropriate treatment option for their individual circumstances.